Senior economist and head of the Department of Economics at UWI St Augustine, Dr Daren Conrad is cautioning that recent backpay disbursements to public-sector workers are unlikely ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...
(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, has announced on Friday a private investment in public equity financing of up to approximately $175 million. The ...
CAMBRIDGE, Mass. - ProMIS Neurosciences Inc. (NASDAQ:PMN) has entered into a securities purchase agreement with institutional and accredited investors to raise up to $175 million through a private ...
CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the generation and ...
Hosted on MSN
ProMIS Neurosciences regains Nasdaq compliance
ProMIS Neurosciences ( (PMN)) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ...
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results